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A B S T R A C T
Iron dyshomeostasis is implicated in Alzheimer’s disease (AD) alongside β-amyloid and tau pathologies. Despite
the recent discovery of ferroptosis, an iron-dependent form cell death, hitherto, in vivo evidence of ferroptosis in
AD is lacking. The present study uniquely adopts an integrated multi-disciplinary approach, combining protein
(Western blot) and elemental analysis (total reflection X-ray fluorescence) with metabolomics (1H nuclear
magnetic resonance spectroscopy) to identify iron dyshomeostasis and ferroptosis, and possible novel interac-
tions with metabolic dysfunction in age-matched male cognitively normal (CN) and AD post-mortem brain tissue
(n = 7/group). Statistical analysis was used to compute differences between CN and AD, and to examine as-
sociations between proteins, elements and/or metabolites. Iron dyshomeostasis with elevated levels of ferritin, in
the absence of increased elemental iron, was observed in AD. Moreover, AD was characterised by enhanced
expression of the light-chain subunit of the cystine/glutamate transporter (xCT) and lipid peroxidation, re-
miniscent of ferroptosis, alongside an augmented excitatory glutamate to inhibitory GABA ratio. Protein, ele-
ment and metabolite associations also greatly differed between CN and AD suggesting widespread metabolic
dysregulation in AD. We demonstrate iron dyshomeostasis, upregulated xCT (impaired glutathione metabolism)
and lipid peroxidation in AD, suggesting anti-ferroptotic therapies may be efficacious in AD.
1. Introduction
Prevailing evidence suggests iron (metal) dyshomeostasis as a con-
tributing factor in Alzheimer’s disease (AD) pathogenesis, alongside
amyloid plaques and tau tangles [1–3]. Clinical trials aimed at at-
tenuating brain amyloid levels have failed to halt AD progression [4]
suggesting other factors at play. Indeed, despite being amyloid-Positron
Emission Tomography (PET)-positive, suggestive of a diagnosis of AD,
30% of individuals remain cognitively normal (CN) [5]. Iron dysho-
meostasis has been proposed to be an additional factor in AD pathology
as severe cognitive decline was shown to correlate with an elevated
brain iron signal in amyloid-PET positive individuals [6].
Brain iron levels undergo strict regulation through import (trans-
ferrin or non-transferrin mediated) and export mechanisms (involving
ceruloplasmin/ferroportin, Cp/Fpn), while intracellular iron is seques-
tered by ferritin [7–9]. The perturbed brain iron regulation in AD en-
ables redox-active ferrous iron to both generate hydroxyl free radicals
in the Fenton reaction and induce/enhance neuroinflammation, con-
tributing to oxidative stress and neurodegeneration possibly via an iron-
dependent cell death called ferroptosis [6,10–13]. During the process of
ferroptosis, iron-induced lipid peroxidation causes catastrophic mem-
brane rupture in conditions of diminished activity of a lipid repair en-
zyme, glutathione peroxidase 4 (GPX4) [14]. GPX4 utilises glutathione
as a cofactor, with cysteine availability being the rate limiting factor in
glutathione synthesis. The cystine/glutamate transporter (Xc-) uptakes
cystine (oxidised cysteine) into the cell in exchange for glutamate. In-
hibition of Xc- depletes glutathione levels and impairs GPX4 activity,
thereby increases lipid peroxidation. Certain membrane lipids have
been found to be oxidised during ferroptosis. Polyunsaturated fatty
acids (PUFA) specifically containing arachidonic acid are esterified
with CoA by Acyl-CoA synthetase long chain family member 4 (ACSL4)
forming phosphatidylethanolamines [15], which are vulnerable to
peroxidation by iron-dependent lipoxygenases [16].
Iron dyshomeostasis alongside impaired activity of Xc- [17-20] and
lipid peroxidation [11] are features of ferroptosis [10], which could
provide successful therapeutic targets to attenuate AD. However, in vivo
evidence of such ferroptosis-related processes in human AD is lacking
and our study aims to determine the expression levels of proteins
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implicated in iron metabolism and ferroptosis in CN and AD brains.
Total X-ray Reflection Fluorescence (TXRF) was also used to measure
brain contents of iron and other elements, which we have shown to
discriminate between plasma from CN and AD subjects [2]. Further, in
a unique integrated, multi-disciplinary approach, protein and elemental
analyses were combined with 1H NMR based metabolomics to identify
iron dyshomeostasis and possible novel interactions with metabolic
dysfunction in AD. Metabolic derangements have been observed pre-
viously by 1H NMR metabolomics in AD post-mortem brain tissues [21]
and animal models [22]. We hypothesised that iron dyshomeostasis,
augmented lipid peroxidation and impaired Xc-, characteristics of fer-
roptosis, would be observed in AD. We also conjectured interactions
within and between protein, elements/metals and metabolite networks
to differ between CN and AD.
2. Material and methods
2.1. Samples
Frozen samples of human medial temporal gyri were obtained from
the London Neurodegenerative Diseases Brain Bank (LNDBB, Brains for
Dementia research) with ethical approval (London – City and East NRES
committee 08/H0704/128 + 5). Samples were obtained from male CN
subjects with no history of dementia and male AD patients (n = 7/
group) with clinically and pathological confirmed AD (Braak Stage 6;
Table 1). An overview of the study protocol is shown in Fig. 1.
2.2. Western blotting
2.2.1. Sample preparation
Brain tissues (~33 mg) were extracted with 500 μl radio-
immunoprecipitation assay buffer (RIPA; 1% Triton X-100, 1% sodium
deoxycholate, 0.1% sodium dodecyl sulphate, 150 mM NaCl and 50 mM
Tris-HCl, pH 7.2; 89901, Thermofisher, UK), supplemented with pro-
tease/phosphatase/EDTA inhibitor cocktail (87785, Thermofisher, UK)
and sonicated (30 s). Following centrifugation (14,800 g, 20 min, 4°C),
supernatants/lysates were stored at −80°C until further analysis.
2.2.2. Western blot (WB) analysis
Lysates (containing 40 μg protein, determined using a Thermo
Nanodrop Spectrophotometer ND 1000) were mixed with laemmli
buffer (S3401; Sigma, Poole, UK) and heated (95 °C, 5 min). Proteins
were separated on NovexTM Tris-glycine 4–20% gradient gels
(XP04205BOX, Thermofisher) at 150 V, 90 min and then transferred
onto a 0.45 μm nitrocellulose membrane (GE10600002, GE healthcare,
Amersham, UK) in Tris-glycine buffer supplemented with 20% me-
thanol (80 V, 1 h). Membranes were incubated in a blocking solution
(5% milk in PBS-0.2% Tween, 1 h, ambient temperature), prior to with
primary antibodies (Supplemental Table S1; overnight, 4°C) including
iron-associated proteins: ferritin-light chain (FTL), ferritin-heavy chain
(FTH), transferrin-receptor (TfR), divalent metal transporter 1 (DMT1),
Iron Responsive Element Binding Protein 2 (IREB2), Cp, Fpn, heme-
oxygenase-1 (HO-1), melanotransferrin (MTf), lactoferrin (LTf); and for
ferroptosis, Nuclear factor erythroid 2-related factor 2 (Nrf2), ACSL4,
light-chain subunit of Xc- (xCT), GPX4 and the lipid-peroxidation
marker 4-hydroxynonenal (4-HNE). After incubation, membranes were
washed (3 x 5 min, PBS-0.2% Tween) and then incubated with horse
radish peroxidase (HRP)-conjugated secondary antibodies (Thermo-
fisher; Supplemental Table S1) in 5% milk/PBS-0.2% Tween (1 h,
ambient temperature). After washing (PBS-0.2% Tween, 3 x 5 min),
membranes were visualised (Pierce ECL western blotting substrate,
32106; Thermofisher) and imaged (BioRad ChemiDoc MP system).
Membranes were stripped using restore Western blot stripping buffer
(20159; Thermofisher) and re-probed with HRP-conjugated β-actin.
Band signal intensities were quantified by densitometry (ImageJ soft-
ware 2.0, NIH), and normalised to β-actin.
2.3. Total reflection X-ray fluorescence (TXRF)
2.3.1. Sample preparation
Lysates were thawed and diluted 1:4 v/v with distilled water.
Polyvinyl alcohol (2 μl, 0.3 g/l water; 843871, Merck, Gillingham, UK)
was added to the diluted lysate (10 μl). Gallium solution (10 μl, 440g/l;
TraceCERT® gallium standard for inductive coupled plasma; 16639,
Merck) was also added (200 μg/l final concentration). After thorough
mixing, 10 μl of the resultant solution was centrally placed onto an
acrylic sample carrier (Bruker Nano GmbH, Germany) and air dried:
duplicates were prepared, readings recorded and averaged.
Supplemented RIPA buffer for tissue homogenisation was also prepared
for TXRF as detailed above.
2.3.2. TXRF data acquisition and analysis
Samples were analysed on a TXRF spectrometer with a molybdenum
tube excitation source operating at 50 kV/600 μA (S2 PICOFOX™,
Bruker Nano GmbH) and data were collected over 1000 s. After in-
spection and elemental identification of TXRF spectra, spectra were
deconvolved using PICOFOXTM software. Elemental concentrations of
iron, copper, zinc, calcium and phosphorus were calculated by
Table 1
Demographic details of cognitively normal (CN) and Alzheimer’s disease (AD) subjects in this study. The post-mortem delay (PMD) and post-mortem interval (PMI)
are the time intervals between death and brain removal, and between death and when the brain was frozen, respectively. Age, post-mortem delay (PMD) and post-








1 Cognitively normal 96 43 68 Braak Stage II - Pathological changes consistent with aging
2 82 26 27 Modified Braak Stage II – Very mild AD pathology
3 77 11 11 Normal
4 73 23 23 Normal
5 74 22.5 24 Modified Braak Stage I with mild amyloid angiopathy
6 91 47 51 Braak Stage II – pathological changes consistent with normal aging
7 80 31 54 Braak Stage II – pathological changes consistent with normal aging
mean ± standard deviation 82 ± 9 29 ± 12 37 ± 19
8 Alzheimer’s disease 72 61 89 Modified Braak Stage VI with mild amyloid angiopathy
9 81 30 58 Modified Braak Stage VI with mild amyloid angiopathy
10 62 23 23 Modified Braak Stage VI with mild amyloid angiopathy
11 79 20 24 Modified Braak Stage VI with moderate amyloid angiopathy
12 70 20 20 Modified Braak Stage VI with extensive amyloid angiopathy
13 76 90 114 Braak Stage VI with TDP43 pathology limited to amygdala
14 90 44 69 Braak Stage VI - CERAD age related plaque score C (definite)
mean ± standard deviation 76 ± 9 41 ± 26 57 ± 34
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reference to the internal gallium standard, elemental contributions
from the supplemented RIPA buffer subtracted, and normalised to
protein concentrations (mg/g protein).
2.4. 1H NMR spectroscopy
2.4.1. Sample preparation
Frozen brain tissue (~40 mg) underwent dual phase extraction with
chloroform-methanol-water to provide aqueous and organic extracts.
Tissue was ground to a fine powder with a pestle in a cardice-chilled
mortar and then transferred into a solvent resistant tube (Nalgene™
OakRidge centrifuge tubes, ThermoFisher) containing methanol (2 ml;
AnalaR grade; VWR Chemicals, Lutterworth, UK). Deionised water
(2 ml) and chloroform (2 ml; AnalaR grade; Sigma-Aldrich, Poole, UK)
was then added to the tube and the sample thoroughly mixed and
centrifuged (10000 g, 10 min). After centrifugation, aqueous and or-
ganic phases were collected into separate tubes. The tissue pellet was
then washed/mixed with more methanol, distilled water and chloro-
form (2 ml of each), centrifuged and the phases again separated and
pooled with the appropriate previous collections.
To each aqueous and organic phase samples, trimethylsilyl-
[2,2,3,3,-2H4]-propionate (TSP; Sigma-Aldrich, Poole, UK), a con-
centration and chemical shift (δ) reference standard was added (10 μl,
2.0 mg/ml deuterium oxide, Sigma-Aldrich), the solution mixed and
then lyophilized. Prior to lyophilisation, methanol and chloroform were
removed from the organic phase by a stream of nitrogen gas. For 1H
NMR, the aqueous and organic phases were reconstituted in phosphate
buffer (pH 7.0, 100 μl) and deuterium oxide (500 μl), and 500 μl
deuterochloroform, respectively, transferred to a 5 mm NMR tube
(Wilmad 507-PP, Apollo Scientific, UK) and stored at −20 °C prior to
analysis.
2.4.2. 1H NMR acquisition and analysis
1D and 2D 1H NMR were performed on a Bruker Avance III NMR
spectrometer (Bruker Biospin, Karlsruhe, Germany) operating at
500 MHz 1H frequency.
2.4.2.1. 1D-1H NMR. Aqueous phase: Spectra for aqueous extracts of
brain were acquired using a 1D-1H-NOESY sequence with presaturation
to attenuate the water resonance. Fully T1-relaxed spectra were
collected with a relaxation delay of 2.00 s and acquisition time of
5.46 s. In total, 256 scans were collected with four dummy scans into
64k data points and 6000 Hz spectral width. Spectra were processed
using Topspin (v 3.5, Bruker Biospin, Karlsruhe, Germany) with
application of 0.2 Hz exponential line broadening, baseline corrected
and referenced to trimethylsilyl-[2,2,3,3,-2H4]-propionate (TSP; Sigma-
Aldrich, Poole, UK): a typical 1H NMR spectrum of the aqueous fraction
is shown in Fig. 2. Using Chenomx™ (v8.4; Edmonton, Canada), the
following metabolites were identified and quantified (mmol/g wet
tissue weight): acetate, alanine, aspartate, carnitine, choline, creatine,
formate, fumarate, GABA (γ-aminobutyrate), glutamate, glutamine,
glycine, glycerol, hypoxanthine, inosine, isoleucine, leucine, myo-
inositol, N-acetylaspartate (NAA), phenylalanine, succinate, tyrosine
and valine. 1H-J-resolved (JRES) and 1H-1H correlation NMR
spectroscopy (COSY) were also performed to aid/confirm metabolite
identification (see below).
Organic phase: 1D-1H NMR spectra were collected using a pulse-
collect sequence and again fully T1-relaxed spectra was collected but
with a relaxation delay of 2.00 s and acquisition time of 5.03 s. In total,
128 scans were collected with four dummy scans into 64k data points
and 6510 Hz spectral width. Spectra were processed as for the aqueous
samples using Topspin (v 3.5, Bruker Biospin) and again referenced to
TSP, a typical 1H NMR spectrum of the organic phase is shown in Fig. 3.
Characteristic resonances of fatty acids, PUFAs, triglycerides and cho-
lesterol were identified and quantified (μmol/g wet tissue weight).
Fig. 1. Overview of multidisciplinary techniques used in study protocol involving western blotting, total X-ray reflection fluorescence (TXRF) and 1H nuclear
magnetic resonance (NMR) spectroscopy of human medial temporal cortical post-mortem tissue. Abbreviations: trimethylsilyl-[2,2,3,3,-2H4]-propionate (TSP),
deuterium oxide (D2O), deuterochloroform (CDCl3) and radioimmunoprecipitation assay buffer (RIPA).
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2.4.2.2. 2D-NMR. 1H-1H Correlation spectroscopy (COSY) and 1H-J-
resolved (JRES) NMR were also performed to aid/confirm metabolite
identification.
1H-1H COSY NMR: COSY-NMR is used to determine correlations
through chemical bonds and aids to determine resonances that are
mutually coupled, usually up to four bonds. COSY data is plotted as a
2D, both axes being frequency axes, and “cross peaks” appear away
from the diagonal axis when protons are coupled to each other. For the
aqueous phase collected following dual phase extraction of medial
temporal cortical tissue, a phase-sensitive COSY sequence was used
with presaturation of the water resonance during the 2 s relaxation
delay. Gradient pulses were used for selection of cross peaks, 256 in-
crements of 4k data points were collected over a 6000 Hz sweep width,
with 64 scans per increment. Spectra were zero-filled to 4k datapoints
and a sine window function applied in both dimensions prior to Fourier
transformation. Typical COSY NMR spectra of the aqueous phase are
shown in Figs. 4A and 5. For the organic phase, a phase-sensitive but
double quantum filter, COSY pulse sequence was used. Again gradient
pulses were used for cross peak selection, 256 increments of 2k data
points collected over a 6510 Hz sweep width, with 40 scans per in-
crement collected and a relaxation delay of 1.5 s. Spectra were zero
filled to 4k points and a sine function was applied in both dimensions
Fig. 2. Typical partial 1H nuclear magnetic resonance spectrum of the δ 0.80 – 8.70 ppm region (excluding δ 4.50 - 5.80 ppm) of the aqueous phase obtained
following dual phase extraction with chloroform, methanol and water of medial temporal cortex of a cognitively normal subject. Resonances from formate and lactate
have been truncated. Assignments are based on Chenomx™, literature values (see Supplemental) and from 1H-JRES and 1H-1H COSY data (see Figs. 4 and 5).
Abbreviation: γ-aminobutyrate (GABA).
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prior to Fourier transformation.
1H J-resolved NMR spectroscopy (JRES): 2D JRES is another 2D-
NMR technique that aids identification of resonance multiplicities.
JRES NMR spectra has the chemical shift along one axis and the proton-
proton coupling along the other axis. Spectra were carried out using a
JRES sequence with presaturation of the water resonance during the 2 s
relaxation delay. Gradient pulses were used for selection, a total of 80
increments of 16 k points over a sweep width 6000 Hz and 32 scans per
increment were collected. Spectra were zero filled to 16 k and a sine
function was applied in both dimensions prior to Fourier transforma-
tion. Typical JRES NMR spectra of different regions of the spectrum of
an aqueous phase sample obtained following dual phase extraction of
medial temporal cortical tissues are shown in Figs. 4B and 5.
2.5. Statistical analysis
Statistical analysis was performed using IBSS SPSS statistics 24. A
two-tailed t-test was used to compute differences between CN and AD
and Pearson’s correlation analysis to examine association between
variables. Data normality was assessed using Q-Q, residual and homo-
scedasticity plots: values violating these assumptions were identified as
outliers and excluded from analysis. Values are recorded as
mean ± standard deviation (S.D.) and t-values and degrees of freedom
(df) provided. Significance was set at p≤0.05, with *, **, *** and ns,
being p<0.05, p<0.01, p<0.005 and not significant, respectively.
3. Results
The authors confirm that the data supporting the findings of this
study are available within the article and the supplemental.
3.1. Western blot
Western blot analysis suggested iron dyshomeostasis, with sig-
nificantly increased expression of iron-storage proteins, FTL
(p=0.0420) and FTH (p=0.0137), in AD compared to CN
(Supplemental Table S2, Fig. 6). Ferroxidase Cp expression was aug-
mented in AD brains (p=0.0173), whilst decreasing trends were
observed for DMT1 (p=0.0617) and iron-exporter Fpn expression
(p=0.0655). Moreover, xCT expression (p=0.0486) and the lipid
peroxidation product, 4-HNE (p=0.0003) were significantly elevated in
AD, implicating ferroptosis as a mechanism operant in AD. The pro-
teins: IREB2, TfR, HO-1, MTf, LTf, Nrf2, ACSL4 and GPX4 were not
significantly altered in AD compared to CN (Supplemental Table S2,
Supplemental Fig. S1).
3.2. TXRF
Iron dyshomeostasis may alter brain iron levels and so TXRF was
used to quantify elemental iron concentrations. Elemental copper, zinc,
calcium and phosphorus levels were also measured as we have pre-
viously found alterations in their plasma levels in AD [2]. The iron
levels in the temporal cortex were similar (p=0.6494; Table 2) between
groups but zinc was significantly diminished in AD compared to CN
(p=0.0411; Table 2; Fig. 7). Meanwhile, elemental concentrations of
copper (p=0.5158), calcium (p=0.8136) and phosphorus (p=0.4356;
Table 2) were comparable between CN and AD.
3.3. 1H NMR spectroscopy
Metals are often essential cofactors in metabolic reactions and can
modulate metabolism. Thus, 1H-NMR-based metabolomics was used to
assess metabolite levels, particularly those involved in neuronal func-
tion.
Expectedly, GABA (p=0.0517) showed a trend of decrease in AD
post-mortem tissue (Fig. 8) but glutamate levels were similar in AD and
CN tissues (p=0.4986). However, the glutamate to GABA, or ex-
citatory: inhibitory ratio, was significantly enhanced in AD, reminiscent
of increased excitotoxicity (p=0.0035). Meanwhile, glutamine
(p=0.0111) and NAA (p=0.0205) were found to be significantly de-
creased in AD tissues (Fig. 8, Supplemental Table S3). Other metabo-
lites, creatine (p=0.0520) and glycerol (p=0.0538), demonstrated a
trend of decrease in AD (Fig. 8). Further, hypoxanthine levels were
decreased in AD (p=0.0397), while a trend of decrease was apparent
for inosine (p=0.0530; Fig. 8, Supplemental Table S3). The levels of
fatty acids (p=0.0707), PUFA (p=0.0949), triglycerides (p=0.1570),
Fig. 3. Typical partial 1H nuclear magnetic resonance spectrum of the δ 0.75 – 6.00 ppm region of the organic phase obtained following dual phase extraction with
chloroform, methanol and water of tissue from the medial temporal lobe of a cognitively normal subject. The overlapping methylene resonances from the fatty acid
chains have been truncated. Assignments are based on literature values. Abbreviations: fatty acid chains (FA), polyunsaturated fatty acids (PUFA) and triglycerides
(TG).
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cholesterol (p=0.4524) were similar between CN and AD groups
(Supplemental Table S3).
3.4. Correlation analysis
Correlations within aqueous phase metabolite and element net-
works were more apparent in CN compared to AD but comparable for
the organic phase metabolite network (Fig. 9).
A variation in correlation profile was observed for CN compared to
AD for the aqueous and organic phase metabolites network (Fig. 9).
Closer inspection shows GABA was positively associated with creatine
(r=0.895, p=0.006**), glutamate (r=0.885, p=0.008**), NAA
(r=0.817, p=0.025*), hypoxanthine (r=0.786, p=0.036*), phenyla-
lanine (r=0.796, p=0.032*) and calcium (r=0.916, p=0.004***) in
CN, while a trend of positive correlation was evident between GABA
and glutamine (r=0.745, p=0.055ns; Fig. 10). Conversely, in AD sub-
jects, a significant association was observed between GABA and gluta-
mate (r=0.936, p=0.006**), but none were observed with creatine
(r=0.777, p=0.069ns), NAA (r=0.750, p=0.086ns), hypoxanthine
(r=0.757, p=0.081ns), phenylalanine (r=0.282, p=0.588ns), calcium
(r=0.506, p=0.384) or glutamine (r=−0.361, p=0.482; Fig. 10).
Higher levels of fatty acids were associated with increased FTL
(r=0.937, p=0.019*) but lower levels of NAA (r=−0.816, p=0.025*)
and GPX4 (r=−0.880, p=0.009**) in CN but not in AD (Fig. 9).
However, higher fatty acid levels were correlated to higher IREB2
(r=0.814, p=0.049*) in AD but not in CN (r=−0.073, p=0.876ns).
Meanwhile, higher cholesterol was associated with lower levels of FTH
(r=−0.902, p=0.037*) and GPX4 (r=−0.852, p=0.015) only in CN.
Also, a negative correlation was observed between triglyceride and
GPX4 levels (r=0.792, p=0.034*) in CN but not in AD (r=−0.033,
p=0.951ns). Higher levels of PUFA were associated with increased
IREB2 in AD (r=0.845, p=0.017*) but not in CN (r=0.484,
p=0.271ns).
In CN, higher calcium was associated with higher NAA (r=0.867,
p=0.011*), but lacking in AD (r=0.337, p=0.580ns; Fig. 9). Im-
portantly, higher iron was associated with augmented phosphorus
Fig. 4. Typical partial (A) 1H-1H COSY and (B) 1H-JRES nuclear magnetic resonance (NMR) spectra (with the corresponding 1D-1H NMR spectrum) of an aqueous
phase sample obtained from dual phase extraction of human medial temporal gyrus tissue. Abbreviations include: N-acetyl-aspartate (NAA) and γ-aminobutyric acid
(GABA).
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(r=0.862, p=0.013*), copper (r=0.879, p=0.009**), zinc (r=0.823,
p=0.023*) and Cp (r=0.893, p=0.007**) in CN, but not in AD
(Fig. 11). Interestingly, there was a trend of negative correlation be-
tween iron and Cp in AD (r=−0.807, p=0.052ns; Fig. 11). Moreover,
elevated iron was significantly associated with higher glutamine
(r=0.89, p=0.039*), TfR (r=0.816, p=0.048*) and HO-1 (r=0.484,
p=0.033*), but lower hypoxanthine (r=−0.904, p=0.035*) in AD
(Fig. 11). Similarly, higher FTL correlated to higher TfR (r=0.889,
p=0.018*), and a trend of negative association between FTL and GPX4
(r=−0.804, p=0.054ns) in AD (Fig. 9). The ferroxidase ferritin sub-
unit, FTH, was negatively associated with iron (r=−0.908, p=0.033*)
in CN, whereas in AD, augmented FTH levels were correlated to lower
Fpn levels (r=−0.865, p=0.026*; Fig. 11).
Focussing on associations with proteins involved in ferroptosis,
Fig. 5. Typical partial 1H-1H-COSY nuclear magnetic resonance (NMR) spectrum (with the corresponding 1D-1H NMR spectrum) of an aqueous phase sample
obtained from dual phase extraction of human medial temporal gyrus tissue.
Fig. 6. Expression levels of ferritin-light chain (FTL), ferritin-heavy chain (FTH), ceruloplasmin (Cp), ferroportin (Fpn), cystine/glutamate transporter (Xc-) and 4-
hydroxynonenal (4-HNE) adducts in the medial temporal cortex of cognitively normal (CN) and Alzheimer’s disease (AD) subjects, along with representative western
blots. Graph presents individual values and the mean ± standard deviation. A p-value ≤ 0.05 was considered significant; with * and ***, p < 0.05 and 0.005,
respectively.
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upregulated xc- was associated with increased DMT1 (r=0.974,
p=0.005**) and lower LTf (r=−0.847, p=0.033*) in AD and not
observed in CN (Fig. 9). Also, higher ACSL4 correlated to attenuated
GPX4 in AD (r=−0.783, p=0.037*) but not in CN (r=−0.347,
p=0.445ns). In the latter, elevated GPX4 was associated with increased
NAA (r=0.791, p=0.034*) but absent in AD (r=0.632, p=0.178ns;
Fig. 9). Lower 4-HNE was associated with higher DMT1 (r=−0.884,
p=0.019*) in CN. However, in AD, augmented levels of 4-HNE corre-
lated to higher levels of MTf (r=0.839, p=0.037*; Fig. 9).
4. Discussion
We demonstrate ferroptotic-like changes in the AD brain, with
evidence of iron dyshomeostasis, increased expression of xCT and lipid
peroxidation, co-existent with augmented excitatory glutamate: in-
hibitory GABA ratio. These combined metal/elemental, molecular and
metabolic findings implicate oxidative stress and impaired glutathione
antioxidation, concomitant with iron dyshomeostasis to be operant in
AD (Fig. 12) and suggests therapies targeting ferroptosis are potentially
beneficial.
AD brains exhibited augmented expression of iron-storage proteins,
FTH and FTL, hinting towards an increase in the labile iron pool in AD,
although elemental iron levels were comparable in CN and AD.
Previously, brain iron was reported to both accumulate in AD [6,23]
and to be unaltered [24]. We postulate that despite elevated ferritin,
ferritin’s ability to oxidise and store iron in a non-toxic but bioavailable
form is rendered ineffective and may explain the dissociation between
iron levels and ferritin [25,26]. Indeed, ferritin in the AD brain appears
to be different from physiological ferritin, with catalytic sites available
for Fenton reactions to enhance oxidative stress [27]. Augmented fer-
ritinopathy has been observed in neuroferritinopathy [28] and ferriti-
nopathy is required for bromoprotein BRD4 inhibitor-induced ferrop-
tosis in cancer cells [29]. Also, ferritin aggregate formation in
ferritinopathy may induce functional ferritin deficiency to accentuate
iron-mediated oxidative stress [7,28,30]. Interestingly, increased FTL
was associated with reduced GPX4 levels in AD in our study, suggesting
dysfunctional ferritin detrimentally attenuates brain antioxidant capa-
city, with glutathione levels shown to be reduced in AD [31]. Although
plasma glutathione has been reported to be comparable between CN
and AD, lower glutathione was associated with severe cognitive im-
pairment [32].
We observed compensatory Cp-upregulation in AD, Cp is needed to
oxidise ferrous iron to ferric iron to facilitate Fpn-mediated iron export.
Along with a trend of decreased Fpn expression in AD, a deficiency in
cellular iron efflux is implicated as a mechanism underlying iron dys-
homeostasis. In congruence with our study, Fpn is decreased in human
AD and APP transgenic mouse brains and in response to ischaemia and
inflammation [33–35], the latter inducing hepcidin-upregulation to
internalise and degrade Fpn [34]. The lack of cellular iron egress con-
tributes to an elevation in the labile ferrous iron pool, contributing to
(via the Fenton reaction) lipid peroxidation [11], a signature of fer-
roptosis [10]. Indeed, we observed increased 4-HNE adducts, products
of lipid peroxidation in AD.
Zinc exerts antioxidant effects to potentially ameliorate free-radical
mediated oxidative damage [36]. Interestingly, a zinc-deficient diet
resulted in iron accumulation in the liver, kidney, spleen and testes
[37,38]. We observed significant decrements in brain zinc in AD, al-
luding to decreased antioxidant capacity and enhanced oxidative stress
in a zinc-deficient brain environment [39], consistent with our previous
TXRF study showing decreased plasma zinc in AD [2]. Furthermore,
zinc appears to be intimately involved in the regulation of glutama-
tergic signalling (with ~50% of glutamatergic synapses being zinc-rich)
[40,41], attenuated GABAergic signalling may arise from glutamate-
induced excitotoxicity under conditions of brain zinc deficiency.
The accruing iron-dependent oxidative stress may explain our
finding of upregulated-xCT in AD as a result of Xc--inhibition [42]. The
Xc- antiporter comprises a light-chain subunit (xCT, SLC7A11) and a
heavy-chain subunit (CD98hc, SLC3A2) [42–44], with the latter
Table 2
Elemental concentrations (mg/g protein) in lysates prepared from homogenisation of medial temporal cortical tissue from cognitively normal (CN) and Alzheimer’s
disease (AD) subjects. Data are presented as mean ± standard deviation (sample size). Significance was set at *p ≤ 0.05, and t-value and degrees of freedom (df)






Iron 3.503 ± 1.579 (7) 3.195 ± 0.653 (6) 0.6496 0.472 (8.238)
Copper 0.270 ± 0.110 (7) 0.246 ± 0.105 (7) 0.6803 0.422 (11.98)
Zinc 0.742 ± 0.174 (7) 0.556 ± 0.108 (6) 0.0411* 2.338 (10.15)
Calcium 5.296 ± 1.808 (7) 5.092 ± 1.032 (7) 0.1977 0.259 (9.531)
Phosphorus 214.00 ± 52.00 (7) 200.00 ± 36.00 (7) 0.5786 0.573 (10.77)
Fig. 7. Total Reflection X-ray Fluorescence
(TXRF) measurements of elemental concentrations
of iron, copper, zinc, calcium and phosphorus in
the medial temporal cortex of cognitively normal
(CN) and Alzheimer’s disease (AD) subjects. Graph
shows individual values and the mean ± standard
deviation mg/g protein. The significance
threshold was set at *p ≤ 0.05. Abbreviation: not
significant, ns.
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undertaking the simultaneous import of extracellular cystine and export
of intracellular glutamate [20] (Fig. 12). Intracellular cystine is then
reduced to cysteine (Fig. 12), the rate-limiting precursor for glutathione
synthesis [20]. Thus, Xc--inhibition attenuates glutathione synthesis,
perturbing cellular redox balance and inducing ferroptosis [42]. Oxi-
dative stress upregulates xCT via Nrf2-upregulation [45,46], nuclear
translocation of Nrf2 is required and may explain the observed upre-
gulation of xCT, despite normal Nrf2 expression. Indirect evidence
supporting xCT-upregulation in AD is indicated by increased phos-
phorylation of eukaryotic initiation factor 2α and activating tran-
scriptional factor-4 expression [47]. Increased expression of xCT has
also been reported in mice harbouring human APP mutations or given
Fig. 8. Levels of selected metabolites obtained from dual phase extraction of medial temporal cortical tissues from cognitively normal (CN) and Alzheimer’s disease
(AD) subjects. Graphs shows individual values and the mean ± standard deviation μmol/g wet tissue. Significance was set at a threshold of p ≤ 0.05, with * and **
being p < 0.05 and 0.01, respectively. Abbreviation: not significant, ns.
Fig. 9. Heatmap showing the Pearson’s correlation coefficients between metabolites, metals/elements and proteins measured in the cognitively normal (CN) and
Alzheimer’s disease (AD) groups. Abbreviations are: γ-aminobutyrate (GABA), N-acetylaspartate (NAA), polyunsaturated fatty acids (PUFA), ferritin-light chain
(FTL), ferritin-heavy chain (FTH), transferrin-receptor (TfR), divalent metal transporter 1 (DMT1), Iron Responsive Element Binding Protein 2 (IREB2), ceruloplasmin
(Cp), ferroportin (Fpn), heme-oxygenase-1 (HO-1), melanotransferrin (MTf), lactoferrin (LTf), Nuclear factor erythroid 2-related factor 2 (Nrf2), Acyl-CoA Synthetase
Long Chain Family Member 4 (ACSL4), the light-subunit of the cystine/glutamate antiporter (xCT), glutathione peroxidase 4 (GPX4) and 4-hydroxynonenal (4-HNE).
Note, unsaturation (C]C) refers to quantification of –CH2-CH]CH-CH2- of fatty acid chains.
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hippocampal injections of Aβ [17,19]. Our study demonstrates for the
first time, to the best of our knowledge, increased xCT-expression in
human AD. The new PET tracer for measuring Xc- function, 18F-5-
fluoro-aminosuberic acid [48], will aid determination of whether xCT-
upregulation contributes to glutamate-induced excitotoxicity since xCT
is capable of transport in the absence of the heavy-chain subunit (37).
We observed an augmented excitatory glutamate to inhibitory GABA
ratio, suggesting enhanced glutamate-induced excitotoxicity in AD.
Furthermore, excessive extracellular glutamate has been shown to in-
hibit Xc- and induce ferroptosis [43]. While glutamate was comparable
between CN and AD in our study, 1H NMR is unable to differentiate
between intracellular and extracellular glutamate.
MTf expression was similar in CN and AD but higher MTf was as-
sociated with increased lipid peroxidation in the latter. This is con-
sistent with our previous report of diminished baseline cerebrospinal
fluid (CSF) MTf, associated with lower hippocampal volumes and worse
cognitive scores in mild-cognitive impairment (MCI) [49]. Baseline CSF
MTf was lower in MCI-subjects progressing to AD compared to those
remaining stable. Altered MTf metabolism and its positive association
with lipid peroxidation suggests an important avenue to explore in AD
pathogenesis, although the function of MTf and its exact role in iron
metabolism remains elusive.
In AD, augmented ACSL4 levels were associated with lower levels of
GPX4. ACSL4 is responsible for insertion of arachidonic acid (AA, a
PUFA) into phospholipids, particularly phosphatidylethanolamines,
contributing to formation of 4-HNE adducts/lipid peroxidation pro-
ducts [15,50,51]. Ablation of ACSL4 in mice reduced AA insertion into
phosphatidylethanolamines and formation of 4-HNE adducts, and im-
proved glutathione-mediated detoxification [51], consistent with our
correlation analysis. ACSL4 appears to define cellular lipid composition
and dictate ferroptosis-sensitivity via augmenting lipid peroxidation
[15,50,51].
Glutamine modulates glutamatergic and GABAergic neuro-
transmission to protect against Aβ and hydrogen peroxide-induced
oxidative stress [52]. Our depleted glutamine suggests increased glu-
taminolysis (conversion of glutamine to glutamate via glutaminase;
Fig. 13), which may explain the increased excitatory glutamate to in-
hibitory GABA ratio we observed. Interestingly, glutaminolysis has
been shown to regulate ferroptosis alongside transferrin [53]. In normal
brains, glutamate-activation of post-synaptic receptors e.g. N-methyl-D-
aspartate receptor (NMDAR), is terminated by astrocytic uptake of
glutamate and then its amination to glutamine by ammonia, catalysed
by glutamine synthetase (GS) (Fig. 13), protecting neurons against
glutamate excitotoxicity [52,54]. The depletion of glutamine in AD
brains, may be due to Aβ-mediated oxidation of GS, previously ob-
served in MCI and AD [12]. Not only will GS-inhibition enhance
Fig. 10. Significant and trend Pearson correlations of γ-aminobutyrate (GABA) with metals/elements and metabolites in cognitively normal and Alzheimer’s disease.
Significance is set at p≤0.05, with *, ** and *** being p<0.05, <0.01 and < 0.005, respectively. Abbreviation: N-acetylaspartate (NAA).
Fig. 11. Significant and trend Pearson correla-
tions of iron with proteins, elements/metals and
metabolites in cognitively normal and Alzheimer’s
disease. Significance is set at p ≤ 0.05, with * and
** being p<0.05, <0.01, respectively.
Abbreviations: ferritin-heavy chain (FTH), trans-
ferrin-receptor (TfR), ceruloplasmin (Cp) and
heme-oxygenase-1 (HO-1).
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Fig. 12. Overview of ferroptotic-associated changes in Alzheimer’s disease. Iron dyshomeostasis is observed in the form of increased ferritin levels and decreased
export of iron. The consequent increases in labile iron pool enables redox-active (ferrous) iron to precipitate oxidative stress via Fenton reaction. The upregulated
expression of the light-subunit (xCT) of the cystine/glutamate transporter (Xc-) may contribute to excitotoxicity via NR2B-containing N-methyl-D-aspartate receptors
(NMDARs), evidenced by augmented excitatory glutamate to inhibitory γ-aminobutyrate (GABA) ratio, alongside zinc-deficiency and attenuated glutamine levels,
culminating in lipid peroxidation and iron-dependent cell death, ferroptosis. Abbreviations are: ferritin-light chain (FTL), ferritin-heavy chain (FTH), transferrin-
receptor (TfR), divalent metal transporter 1 (DMT1), Iron Responsive Element Binding Protein 2 (IREB2), ceruloplasmin (Cp), ferroportin (Fpn), heme-oxygenase-1
(HO-1), melanotransferrin (MTf), lactoferrin (LTf), Nuclear factor erythroid 2-related factor 2 (Nrf2), Acyl-CoA Synthetase Long Chain Family Member 4 (ACSL4),
glutathione peroxidase 4 (GPX4), 4-hydroxynonenal (4-HNE), polyunsaturated fatty acids (PUFA), excitatory amino acid transporter (EAAT), and lipid peroxides and
alcohols (Lipid-OOH and Lipid-OH, respectively).
Fig. 13. Overview of selected metabolic pathways involving glutamate, glutamine and γ-aminobutyrate (GABA). Abbreviations: N-acetylaspartate (NAA), S-ade-
nosyl-methionine (SAM), S-adenosylhomocysteine (SAH), inorganic phosphate (Pi).
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excitotoxicity, accumulation of ammonia may induce astrocyte swelling
and dysfunction [55]. Excess brain ammonia has been proposed as a
potential neurotoxic factor in AD [56]. In the hyperammonemic state,
NMDAR-mediated activation of the NO/cGMP pathway is induced with
the production of nitrogen radicals and peroxynitrates [55,57], en-
hancing oxidative stress, which can be counteracted by interaction of
glutamine with NMDAR via attenuation of NO synthesis [55,58]. The
reduced brain creatine we observed in AD is consistent with compen-
satory increased partitioning of arginine to ornithine rather than crea-
tine synthesis to detoxify the prevailing accruing ammonia levels
(Fig. 13). However, brain creatine is mostly obtained from the liver and
kidneys via the blood, although shown to be synthesised in the devel-
oping brain and requisite enzymes have been detected in glia [59].
Phosphorylation of creatine by choline kinase (CK) generates phos-
phocreatine, stores of which continuously and efficiently replenishes
ATP via the reversible CK-catalysed reaction (Fig. 13). Notably, CK
facilitates vesicular glutamate uptake and is one of the three major
specifically oxidised proteins in the AD brain [60], contributing to ex-
citotoxicity and energy deficiency. Creatine has been reported to pro-
tect rat hippocampal neurons against Aβ-toxicity by restoring energy
sufficiency [61] alongside its antioxidant properties [62].
Glycerol and fatty acids can be produced from phospholipids by
degradation of plasma membranes in neurodegeneration [63] (Fig. 12).
Here, we report a decrease in NAA consistent with neuronal death in
AD. While increased glycerol levels would be expected, we demon-
strated a trend of decreased glycerol in AD, consistent with decreased
glycerol, accompanied by an increase in its phosphorylated derivative,
observed previously, suggesting a switch to alternative energy sources
due to impaired glucose utilisation in AD [63]. Indeed, increased glu-
tamate export resulting from xCT-upregulation may contribute to the
energy deficit in AD by decreasing intracellular glutamate availability
for transamination reactions to produce citric acid cycle intermediates
for ATP generation (Fig. 13).
We showed that hypoxanthine levels were depressed and its pre-
cursor, inosine, to exhibit a decreasing trend. Previously, these purine
metabolites were reported to be reduced in frontal cortical tissue of
mild AD but unaltered/increased in the temporal cortex of severe AD
[64]. Disrupted purine metabolism in AD has been demonstrated in
such tissues [65] and metabolomic analyses of CSF taken at post-
mortem [66] and from living subjects [67].
Since this was an exploratory study with a small sample size, p-
value correction was not performed. Future subsequent studies with a
larger sample size are required to confirm the findings of this pre-
liminary study. The post-mortem approach enables direct measurement
of brain iron. Whilst magnetic resonance imaging (MRI) is increasingly
used to image iron in vivo, the strength of the MRI-iron signal is de-
pendent on both the iron concentration and the form of iron present
[25]. Our study design is original by using TXRF to directly quantify
elemental (iron) concentrations in human AD brain tissue, alongside
concomitant analyses of proteins and metabolites from the same sub-
ject. But the study has limitations in that we only measured iron at a
single time-point and did not perform temporal staging of cortical iron
levels during progression of AD. Hence, whether iron acted upstream of
APP or secondary to Aβ-aggregation is unknown and the progression of
cortical iron dyshomeostasis requires elucidation. Information re-
garding the dietary intake or excretion of iron, copper or zinc was not
available. The zinc deficiency in the AD brain we observed may arise
from malnutrition, commonly observed at end-stage AD [2].
We did not evaluate the oxidation state of proteins under in-
vestigation, which could serve as a useful biomarker for oxidative stress
and impact elemental and metabolomic measurements. Another study
limitation is the use of post-mortem human tissues for metabolomic
studies. The agonal state and the inevitable delay between death and
tissue processing may hamper the preservation of some metabolites
whose “lifespan” may vary from seconds to a few hours. Although there
was variability in the age, PMD and PMI between CN and AD, they were
not statistically different. The metabolic changes we observed in AD are
consistent with previous reports.
In conclusion, we demonstrate iron dyshomeostasis, upregulated
xCT (perturbed glutathione metabolism) and lipid peroxidation, sig-
natures of ferroptosis in AD, thus supporting the use of anti-ferroptotic
therapies in AD. Our novel finding of xCT-upregulation suggests caution
must be employed when attempting to inhibit ferroptosis by restoring
glutathione antioxidant capabilities via Xc--targeting, as this may con-
tribute to further excitotoxicity and energy deficiency in AD.
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